Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan has confirmed that it was sued by Cephalon and Cephalon France in connection with the filing of an Abbreviated New Drug Application (ANDA) with the FDA for Armodafinil tablets, 50mg, 150mg and 250mg.
Subscribe to our email newsletter
Armodafinil tablets are the generic version of Nuvigil tablets, which are used to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypnea syndrome, narcolepsy and shift work sleep disorder.
Mylan believes it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for the above-noted strengths of this product and expects to qualify for 180 days of marketing exclusivity upon final FDA approval.
Cephalon and Cephalon France has filed lawsuits in the US District Court for the District of Delaware and the US District Court for the Northern District of West Virginia alleging patent infringement.
Currently, Mylan has 141 ANDAs pending FDA approval representing $87.5 billion in annual brand sales, according to IMS.